Formulary Watch |

The approval follows the FDA’s Oncologic Drugs Advisory Committee voting 5-3 in favor of maintaining the approval despite a confirmatory trial that found Keytruda did not meet the end points of overall survival and progression-free survival.

Florida’s First Choice Neurology has provided Aduhelm to patients through the Biogen access program.

The full results from the Emperor-Preserved trial show Jardiance reduces the risk of hospital and death from heart failure.

The combination bamlanivimab and etesevimab can resume use and distribution to treat mild-to-moderate COVID-19 but only in states where variants resistant to the therapy are low.

Bluebook Rx is a new solution that helps employers and plan sponsors better understand and optimize their prescription drug spending.

ICER’s policy recommendations suggest payers establish step therapy with less expensive systemic agents to allow patients and clinicians to choose from multiple options.

Preliminary research shows Anplag could be repurposed as a heart failure treatment at a lower cost.

Now called Comirnaty, the vaccine is approved for those 16 years and older.

The report found that mavacamten offers benefits but was above the threshold of $150,000 per quality-adjusted life-years.

Including patients in the decision-making process, the authors said, is an important component of patient-centered health care.

The monoclonal antibody had been given an emergency use authorization to treat COVID-19, but the recent spike in cases is driving a shortage in supply.

The move, effective July 15, was the result of a generic now being available.

The therapy is expected to be available by early September.